日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A narrative review of lifestyle management guidelines for metabolic dysfunction-associated steatotic liver disease

代谢功能障碍相关脂肪肝疾病生活方式管理指南的叙述性综述

Ivancovsky Wajcman, Dana; Byrne, Christopher J; Dillon, John F; Brennan, Paul N; Villota-Rivas, Marcela; Younossi, Zobair M; Allen, Alina M; Crespo, Javier; Gerber, Lynn H; Lazarus, Jeffrey V

Longitudinal risk of cirrhosis by steatotic liver disease subtype among 1.5 million individuals in the US

美国150万人的脂肪肝疾病亚型与肝硬化纵向风险的关系

Sedki, Mai; Yang, Zeyuan; Singal, Ashwani K; Pessoa, Mário Guimarães; Krag, Aleksander; Schattenberg, Jörn M; Henry, Linda; Alqahtani, Saleh; Lazarus, Jeffrey V; Younossi, Zobair M; Wong, Robert J

Clinical Outcomes and Non-Invasive Testing in Metabolic Dysfunction-Associated Steatohepatitis With Cirrhosis: A Systematic Review

代谢功能障碍相关性脂肪性肝炎伴肝硬化的临床结局和非侵入性检测:系统评价

Hagström, Hannes; Hellmund, Chris; Lazarus, Jeffrey V; Ota, Riku; Rinella, Mary E; Sebastiani, Giada; Tefos, Fotis; Younossi, Zobair M; Noureddin, Mazen

Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis

瑞美替罗治疗后,MASLD 患者(从早期 MASH 到 MASH 肝硬化)的健康相关生活质量得到改善

Younossi, Zobair M; Nader, Fatema; Labriola, Dominic; Taub, Rebecca; Racila, Andrei; Henry, Linda; Stepanova, Maria

Self-Reported Cognitive Function in Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Post-hoc Analysis of the MAESTRO Resmetirom Trials

代谢功能障碍相关脂肪肝病和代谢功能障碍相关脂肪性肝炎患者的自我报告认知功能:MAESTRO Resmetirom试验的事后分析

Younossi, Zobair M; Nader, Fatema; Labriola, Dominic; Taub, Rebecca; Racila, Andrei; Henry, Linda; Stepanova, Maria

Cost of hepatic decompensation and liver transplantation events in primary biliary cholangitis: a retrospective observational study

原发性胆汁性胆管炎肝功能失代偿和肝移植事件的成本:一项回顾性观察研究

Gish, Robert G; MacEwan, Joanna P; Liu, Yutong; Lebovitch, Dannielle; Nair, Radhika; Bessonova, Leona; Li, Jing; Younossi, Zobair M

Impact of Fibrotic Metabolic Dysfunction-Associated Steatohepatitis as a New Indication on Semaglutide Eligibility in the US Adult Population

纤维化代谢功能障碍相关性脂肪性肝炎作为一项新适应症对美国成年人群使用司美格鲁肽的资格的影响

van Kleef, Laurens A; Michel, Maurice; Savas, Mesut; Pustjens, Jesse; Theel, Willy; van Rossum, Elisabeth F C; Paik, James M; Younossi, Zobair M; Janssen, Harry L A; Labenz, Christian; Schattenberg, Jörn M; Brouwer, Willem P

Validation of an Electronic Health Record Algorithm for Identifying Housing-Related Needs in a Safety-Net Health System

在安全网医疗系统中验证用于识别住房相关需求的电子健康记录算法

McCann, Nicole C; de Cuba, Stephanie Ettinger; Hofman, Melissa; Pauly, Tyler; Ashe, Erin; Younossi, Youssef; Stein, Michael D; Shafer, Paul R; Hsu, Heather E

Epidemiology of metabolic dysfunction-associated steatotic liver disease

代谢功能障碍相关脂肪肝疾病的流行病学

Younossi, Zobair M; Kalligeros, Markos; Henry, Linda

Call to action-Pediatric MASLD requires immediate attention to curb health crisis

行动呼吁——儿童急性炎症性肝病需要立即关注,以遏制这场健康危机。

Hartmann, Phillipp; Mouzaki, Marialena; Hassan, Sara; Kehar, Mohit; Mysore, Krupa R; Mauney, Erin; Nonga, Dieudonne; Karjoo, Sara; Sood, Shilpa; Tou, Andrea; Brichta, Christine; Herdes, Rachel E; Pai, Nikhil; Garner, Donna K; Rinella, Mary E; Noureddin, Mazen; Younossi, Zobair; Allen, Alina M; Sanyal, Arun; Kohut, Taisa; Kohli, Rohit; Ramirez, Charina M; Xanthakos, Stavra; Vos, Miriam B; Schwimmer, Jeffrey B; Ibrahim, Samar H; Panganiban, Jennifer